




# *NIDA Responds to the Syndemic of Opioids, Viral Hepatitis and HIV*




**Wilson M. Compton, M.D., M.P.E.**  
Deputy Director, National Institute on Drug Abuse

# Virtually **All of the U.S.** Have Increased Drug Overdoses: Estimated Age-adjusted Death Rates per 100,000 for Drug Poisoning by County.




**63,362 Deaths in 2016**  
**(42,249 from Prescription and Illicit Opioids)**



# Evolution of the Opioid Overdose Deaths:

*Analgesics* ➔ *Heroin* ➔ *Fentanyl*



# Viral Hepatitis , HIV and Opioid Addiction are Part of a *Syndemic* of Intersecting Epidemics


Viral Hepatitis, HIV, and opioid addiction are co-occurring epidemics.

- *Shared risk factors and causes*
- *Cross-cutting benefits of treatment*

*HIV* (and *Hepatitis C*) Outbreak  
Linked to Oxymorphone Injection  
Use in Indiana, 2015


Peters et al.  
*The New England Journal of Medicine*  
2016;375:229-239

Centers for Disease Control and Prevention  
**MMWR**  
Early Release / Vol. 64  
Morbidity and Mortality Weekly Report  
April 24, 2015



*Syndemic Conditions*

# Injection Drug Use Is Driving new Hepatitis C Infections



National Notifiable Diseases Surveillance System (NNDSS)

- Persons who inject drugs are the reservoir (main source) of Hepatitis C infection
- Currently ~750,000 persons who inject drugs in USA
- Surge in Hepatitis C in young persons who inject drugs (18-25 years old)
- Heroin as an initiating opioid has increased sharply


Recommendation to Prevent Hepatitis C: ***Better access to effective OUD treatments – Buprenorphine, Methadone and Naltrexone***

# Combined Use of Syringe Services Programs and Medication Assisted Treatment Reduces HCV Transmission Among People Who Inject Drugs (PWID)

***HCV Infectivity: HCV Remains Infectious Up to 6 Weeks on Improperly Cleaned Surfaces***

## **Syringe Services Programs:**

- **Are an effective component of an integrated approach to reduce HIV/HBV/HCV in PWID**
- **Also offer alcohol swabs, sterile water, condoms, naloxone, testing, and referral to treatment**
- **Reduce overdose deaths and increase entry into treatment**



**Combining high access to syringe programs with MAT reduces risk of HCV infection by**


**74%**

# *How Can NIH/NIDA Research Help?*



# NIH Opioid Research

## *Using Research to End the Opioid Crisis*



# ***New NIH Initiative to Address the Crisis: HEAL: Helping to End Addiction Long-term***

---

- Collaborative, cross-cutting research
  - From basic to behavioral – and everything between
  - Innovative partnerships – across agencies, sectors, organizations – will ensure rapid progress
- **\$500M just added by Congress**
  - Adds to \$600M current funds = \$1.1B for FY18
  - Will propel HEAL
- Advances ***national priorities for pain, addiction research***

# NIDA-Supported Hepatitis C Research

- NIDA: 2<sup>nd</sup> largest NIH funder— \$32.6 M (FY2016)
- Interventions for rural, at-risk women; support for women in drug court; financial literacy & vocational training for at-risk women; tailored prenatal care for pregnant women
- Rapid HCV testing in care settings
- Utilization of case managers within a coordinated care framework




**OraQuick**® Rapid  
Antibody  
Test  
**HCV**

- Adaptation of HIV model of “treatment as prevention”
- Efficacy of direct acting antivirals in substance using populations

# Reported *Hepatitis C* Cases by County, 2013-2014 Combined


# Partnership of *NIDA and Appalachian Regional Commission* (ARC)

- Targeting opioid IDU, OD, HIV and HCV
- One-year planning grants to describe:
  - problem scope
  - contributing health trends
  - Resources, obstacles
- 4 Grants Funded RFA-DA-16-015



*In FY2017 broadened program to include CDC, SAMHSA and ARC*

# *NIDA, CDC, SAMHSA, ARC: Using Research to Combat HIV and Viral Hepatitis in Rural Areas*



# NIDA Joining CDC on the 2018 Update to the *National HIV Behavioral Surveillance among Persons Who Inject Drugs*

**22 MSAs:**



## Plans for 2018

- Improve recruitment of young (<30 years) PWID
- Include HCV testing in NHBS sites
- Expand recruitment outside of urban core

# *Elimination of Hepatitis C*





---

*NIDA and NCI are working with CDC to develop a study of the elimination of HCV in a high-risk community in Kentucky.*

*Work to date includes pilot funding to the University of Kentucky to develop community-based components:*

- *Syringe exchange*
- *Drug treatment*
- *Linkages with criminal justice (because of high-risk persons re-entering the community)*
- *Access to medical care.*
- *Hepatitis C testing and TREATMENT*

[www.drugabuse.gov](http://www.drugabuse.gov)



**NIDAMED** 